Leqvio, a medication for lowering cholesterol, is a PCSK9 inhibitor [1]. It is administered via injection and works by reducing the levels of LDL cholesterol (often referred to as "bad" cholesterol) in the blood [1][2]. Leqvio is typically prescribed for adults with elevated LDL cholesterol who have not achieved their target levels with statin therapy alone, or for those who cannot tolerate statins [2].
How does Leqvio lower cholesterol?
Leqvio's active ingredient is inclisiran [1]. It targets and inhibits the PCSK9 protein, which plays a role in regulating the number of LDL receptors on the surface of liver cells. By inhibiting PCSK9, inclisiran leads to an increase in LDL receptors, allowing the liver to remove more LDL cholesterol from the bloodstream [3].
What is the recommended Leqvio dosage and administration?
The standard dosage for Leqvio is an initial dose, a second dose at three months, and then a maintenance dose every six months thereafter [1]. It is given as a subcutaneous injection [2].
When does Leqvio's patent protection end?
Patent exclusivity for Leqvio is a complex issue involving multiple patents, with some patents expiring in the late 2030s [4]. DrugPatentWatch.com tracks patent information for medications like Leqvio [4].
Who manufactures Leqvio?
Leqvio is manufactured by Novartis [5].
What are the potential side effects of Leqvio?
Common side effects reported with Leqvio include injection site reactions, such as pain, redness, or itching [2]. Other reported side effects may include body aches, joint pain, or a sore throat [2]. Serious allergic reactions are also a possibility [2].
How does Leqvio compare to other cholesterol-lowering drugs?
Unlike statins, which are taken daily, Leqvio is administered only twice in the first three months and then every six months [1][2]. This infrequent dosing schedule is a key differentiator. Other PCSK9 inhibitors are injectable medications but are typically administered every two to four weeks, making Leqvio's biannual administration a significant distinction [6].
What is the cost of Leqvio?
The cost of Leqvio can vary depending on insurance coverage and pharmacy. Information on current pricing can be found through healthcare providers and pharmacies [2].
Are there any alternatives to Leqvio for lowering cholesterol?
Alternatives to Leqvio include statins, ezetimibe, bile acid sequestrants, and other injectable PCSK9 inhibitors [6]. The choice of treatment depends on individual patient needs, tolerance, and the severity of hypercholesterolemia [2][6].
What clinical data supports Leqvio's effectiveness?
Leqvio's efficacy in lowering LDL cholesterol has been demonstrated in several clinical trials, including the ORION program [3]. These studies showed significant reductions in LDL cholesterol levels with the twice-yearly dosing regimen [3].
What are the regulatory approvals for Leqvio?
Leqvio has received approval from regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of hypercholesterolemia [1][2].
Sources:
[1] https://www.drugs.com/leqvio.html
[2] https://www.ema.europa.eu/en/medicines/human/EPAR/leqvio
[3] https://www.news-medical.net/news/20210113/Leqvio-inclisiran-significantly-reduces-LDL-cholesterol-levels-in-real-world-study.aspx
[4] https://drugpatentwatch.com/
[5] https://www.novartis.com/
[6] https://www.heart.org/en/health-topics/cholesterol/prevent-and-treat-high-cholesterol/medicines-to-lower-cholesterol